reports
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity...
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event of pegozafermin’s opportunity in advanced metabolic dysfunction-associated ste...
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ End-of-day, Thursday, May 2, 2024, Will be the Last and Final Day to Trade SAVAW Warrants on NASDAQ.Monday, May 6, 2024, Will be the Last and Final Day to Cash-Exercise SAVAW Warrants.‘Notice of Guaranteed Delivery’ Is Available for Warrant Exercises. AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA) (“Cassava Sciences” or the "Company") has been advised by NASDAQ that end-of-day (“EOD”) tomorrow May 2, 2024, will be the last and final trading day for SAVAW warrants on NASDAQ. After EOD May 2, the ...
Avadel Pharmaceuticals to Provide a Corporate Update and Report First ...
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8 DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. To access the conference call, investors are invited to dial +1 (800) 715-9871 ...
Greene County Bancorp, Inc. Reports Net Income of $18.0 million for th...
Greene County Bancorp, Inc. Reports Net Income of $18.0 million for the Nine Months Ended March 31, 2024 and opens Capital Region Banking Center in Albany, New York CATSKILL, N.Y., April 23, 2024 (GLOBE NEWSWIRE) -- Greene County Bancorp, Inc. (the “Company”) (NASDAQ: GCBC), the holding company for The Bank of Greene County and its subsidiary Greene County Commercial Bank, today reported net income for the three and nine months ended March 31, 2024, which is the third quarter of the Company’s fiscal year ending June 30, 2024. Net income for the three and nine months ended March 31, 2024 w...
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of...
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Martin Babler to its Board of Directors, effective April 13, 2024. Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer and Chairman o...
Greene County Bancorp, Inc. Announces Cash Dividend
Greene County Bancorp, Inc. Announces Cash Dividend CATSKILL, N.Y., April 17, 2024 (GLOBE NEWSWIRE) -- Greene County Bancorp, Inc. (NASDAQ-GCBC) today announced that its Board of Directors has approved a quarterly cash dividend of $0.08 per share on the Company’s common stock. The dividend reflects an annual cash dividend rate of $0.32 per share which is the same rate as the dividend declared during the previous quarter. The cash dividend for the quarter ended March 31, 2024 will be paid to shareholders of record as of May 15, 2024, and is expected to be paid on May 30, 2024. The Compan...
Redemption Date Announced for Warrants
Redemption Date Announced for Warrants Monday, May 6, 2024 is Last and Final Day to Exercise Warrants.Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (“Cassava Sciences” or the "Company") today announced that Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on January 3, 2024 (the “Warrants”). Holders who exercise their Warrants will receive 1.5 shares of Cassava Sciences’ common stock per Warrant, for an eff...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 138,550 shares of the Company’s common stock to eight new employees (the “Inducement...
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcar...
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference on Monday, April 8 at 10:15 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, , for 90 days following the conference. ...
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of M...
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis –PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and ENLIGHTEN-Cirrhosis in MASH patients with compensated cirrhosis (F4) is planned to initiate in the second quarter of 2024– SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharm...
Cassava Sciences Announces Completion of an Interim Safety Review of O...
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification. Final Clinical Safety Data for Simufilam Are Expected at the Conclusion of the Phase 3 Program. AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzhe...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
OPK OPKO HEALTH INC.
NYCB NEW YORK COMMUNITY BANCORP INC.
MHLD MAIDEN HOLDINGS LTD.
GOGO GOGO INC.
DLTR DOLLAR TREE INC.
CTRN CITI TRENDS INC.
CRMT AMERICA'S CAR-MART INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
AAOI APPLIED OPTOELECTRONICS INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
VICI VICI PROPERTIES INC
CDLX CARDLYTICS INC
TALO TALOS ENERGY INC.
STKS THE ONE GROUP HOSPITALITY INC.
PAYS PAYSIGN INC
REEMF RARE ELEMENT RESOURCES
DCTH DELCATH SYSTEMS
RZLT REZOLUTE
MYO INC.
XERS MYOMO
LEE XERIS BIOPHARMA HLDGS INC
QSI LEE ENTERPRISES INC
ASLE QUANTUM-SI INC
VPV AERSALE CORP
BPRN INVESCO PA VALUE MUNI INC TST
CYT BANK OF PRINCETON
CYTEIR THERAPEUTICS INC
- Jonathan Moreland
- Jonathan Moreland
TLYS TILLYS
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
OPK OPKO HEALTH INC.
HOO HERBALIFE NUTRITION LTD.
CTRN CITI TRENDS INC.
CE CELANESE CORPORATION
BANC BANC OF CALIFORNIA INCORPORATED
HWBK HAWTHORN BANCSHARES
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
JFR NUVEEN FLOATING RATE INCOME FUND
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
AYX ALTERYX
FMN FEDERATED PREMIER MUNICIPAL INCOME FUND
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
QNBC QNB CORP.
TALO TALOS ENERGY INC.
RBB RBB BANCORP
AXR AMREP
SKYE NEMUS BIOSCIENCE INC
ELAN ELANCO ANIMAL HEALTH INC.
ANIX ANIXA BIOSCIENCES
PAYS PAYSIGN INC
KSM DWS STRATEGIC MUNICIPAL INCOME TRUST
VTN INVESCO TRUST FOR INVESTMENT G
RZLT REZOLUTE
COOK INC.
MPA TRAEGER
FRST INC.
ASLE BLACKROCK MUNIYIELD PENNSYLVANIA FD
VPV PRIMIS FINANCIAL CORP
BPRN AERSALE CORP
CRBP INVESCO PA VALUE MUNI INC TST
LSXMK BANK OF PRINCETON
BHRB CORBUS PHARMACEUTICALS HOLDINGS INC.
MDRX LIBERTY SIRIUSXM GROUP
APRE BURKE HERBERT FINANCIAL SERVICES CORP
ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS
INC.
APREA THERAPEUTICS INC
- Jonathan Moreland
- Jonathan Moreland
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in No...
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis —Co-primary endpoints in ENLIGHTEN-Fibrosis assessed at week 52 will potentially support accelerated approval in non-cirrhotic MASH (fibrosis stage F2-F3) patients— —ENLIGHTEN-Cirrhosis, the second trial in the program, is planned to evaluate patients with compensated cirrhosis (F4) and is expected to initiate in the second quarter of 2024— SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-...
- Jonathan Moreland
SEDG SOLAREDGE TECHNOLOGIES INC.
PRGO PERRIGO CO. PLC
GOGO GOGO INC.
D DOMINION ENERGY INC
CTRN CITI TRENDS INC.
CLFD CLEARFIELD INC.
CFFN CAPITOL FEDERAL FINANCIAL INC.
HWBK HAWTHORN BANCSHARES
FMC FMC CORPORATION
RIGN TRANSOCEAN LTD.
SPWR SUNPOWER CORPORATION
AFT APOLLO SENIOR FLOATING RATE FUND INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
HCC WARRIOR MET COAL INC.
RBB RBB BANCORP
AXR AMREP
FSK FS KKR CAPITAL CORP
KSM DWS STRATEGIC MUNICIPAL INCOME TRUST
ETNB 89BIO
PCB PACIFIC CITY FINANCIAL CORP
BSBK BOGOTA FINANCIAL CORP.
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
THRY THRYV HOLDINGS
ABCL ABCELLERA BIOLOGICS
LSEA LANDSEA HOMES CORP (A)
LUMN LUMEN TECHNOLOGIES INC.
SLRC SOLAR CAPITAL LTD.
ONDS ONDAS HOLDINGS
PFX PHENIXFIN CORP
WES WESTERN MIDSTREAM PARTNERS LP
ABSI ABSCI CORP
VPV INVESCO PA VALUE MUNI INC TST
GATO SUNSHINE SILVER MINING AND REFINING CORP
LSXMA LIBERTY SIRIUSXM GROUP
LSXMK BURKE HERBERT FINANCIAL SERVICES CORP
BHRB ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS
MDRX INC.
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.